Inhibikase Therapeutics (IKT) Net Cash Flow Growth (3y) (2023 - 2026)
Inhibikase Therapeutics (IKT) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | - |
| 3 | BeOne Medicines | 473.13 Bn | 468.34 Bn | 1.35 Bn | 38.47% |
| 4 | Vertex Pharmaceuticals | 123.67 Bn | 116.43 Bn | 2.59 Bn | 33.37% |
| 5 | Regeneron Pharmaceuticals | 71.57 Bn | 62.81 Bn | 3.31 Bn | -29.82% |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | - |
| 7 | Argenx Se | 54.61 Bn | 49.42 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 37.99 Bn | 34.98 Bn | 959.66 Mn | 32.17% |
| 9 | Revolution Medicines | 36.09 Bn | 36.09 Bn | - | - |
| 10 | Inhibikase Therapeutics | 397.17 Mn | 226.80 Mn | - | -202.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -202.71% |
| Dec 31, 2025 | 315.57% |
| Sep 30, 2025 | -14.31% |
| Jun 30, 2025 | 43.87% |
| Mar 31, 2025 | 82.67% |
| Dec 31, 2024 | 149.70% |
| Sep 30, 2024 | -2.97% |
| Jun 30, 2024 | -73.00% |
| Mar 31, 2024 | -16.18% |
| Dec 31, 2023 | -34.05% |
| Sep 30, 2023 | 1,056.18% |
| Jun 30, 2023 | -626.05% |
| Mar 31, 2023 | -747.36% |